Business Context and Reporting Period
This Form 8-K, filed on April 13, 2026, reports that BiomX Inc. (PHGE) has completed the acquisition of a 60% equity interest in DR. Frucht Systems Ltd. (DFSL), an Israeli developer of LADAR-based detection systems for security and defense applications. DFSL is now a majority-owned operating subsidiary of BiomX.
Key Financial Metrics and Transaction Terms
The transaction consideration for the 60% stake in DFSL includes the following components:
- Cash Payment: $750,000 total, of which $450,000 was previously advanced.
- Convertible Note: Unsecured promissory note of $3,000,000, convertible at BiomX's option into common stock at $12.00 per share.
- Common Stock: Issuance of 923,000 shares.
- Pre-Funded Warrants: Warrants exercisable for 923,000 shares at $12.00 per share.
- Five-Year Warrant: Warrant exercisable for 3,692,000 shares at $12.00 per share.
- Revenue Bonus: Potential future payment of 5% of DFSL's annual revenue if it exceeds $25,000,000 in any fiscal year starting in 2027.
The filing does not provide specific revenue, profit, cash flow, or margin figures for BiomX or DFSL for the current or prior periods.
Material Changes and Contingencies
The primary material change is the expansion of BiomX's operations into laser-based security and defense technology through the acquisition of DFSL. Key contingencies include:
- Stockholder Approval: The issuance of common stock upon conversion of the note and exercise of warrants is subject to NYSE American rules and requires stockholder approval, which BiomX intends to seek within 120 days.
- Regulatory Approval: The transaction is subject to receipt of approval from the Israeli Investment Authority (IIA) regarding the change of control of DFSL.
- Credit Line: Mandragola has agreed to provide a credit line for DFSL's development and debt payments, though specific terms are to be mutually agreed upon.
Outlook and Risks
Management anticipates the integration of DFSL as a majority-owned subsidiary. The filing includes standard forward-looking statements regarding future business prospects and integration success. Significant risks identified include the failure to obtain stockholder or regulatory approvals, integration challenges, and general economic or competitive factors. The securities issued in this transaction were sold under Section 4(a)(2) and Rule 506(b) exemptions and are not registered.
Investor Verification Checklist
- Verify the status of the required stockholder approval for the issuance of shares related to the convertible note and warrants.
- Confirm the receipt of Israeli Investment Authority (IIA) approval for the change of control of DFSL.
- Review the specific terms of the unsecured convertible promissory note and the warrants (Exhibits 4.1, 4.2, and 4.3).
- Assess the financial health and revenue trajectory of DFSL to evaluate the likelihood of triggering the 5% revenue bonus.
- Monitor the finalization of the credit line terms with Mandragola.